# BioMathematica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomathematica

- Industry: Biotechnology
- Headquarters: France
- Website: www.biomathematica.com
- Latest round: Seed (Jun 15, 2018)
- Investors on record: 1

## About

BioMathematica is a French bioinformatics company that leverages mathematical approaches to analyze complex biological systems, focusing particularly on the human microbiome.Founded in 2017, BioMathematica operates out of France and specializes in bioinformatics and Systems Biology. The company has experienced growth through its unique service offerings. CEO Ghjuvan Grimaud leads the firm, which has completed one known deal, securing Seed funding from SOSV in June 2018.Biomathematica specializes in bioinformatics and Systems Biology, focusing on the application of mathematics to complex biological systems, particularly the human microbiome. The company offers an array of services, including end-to-end bioinformatics pipelines for Next Generation Sequencing (NGS) data, addressing various biological analyses such as amplicon sequencing, shotgun metagenomics, metatranscriptomics, metabolomics, and metaproteomics. Their core services are designed to analyze raw data and generate comprehensive analysis reports, facilitating the development of probiotics, prebiotics, and live biotherapeutics targeted at diverse microbiomes including human, animal, and environmental. Biomathematica caters to a diverse clientele across the biotechnology and pharmaceutical sectors, with applications spanning therapeutic development, personalized medicine, and microbiome engineering. The company operates in multiple geographical markets, primarily serving clients in Europe and North America.Biomathematica's revenue model is structured around B2B transactions, engaging with clients in the life sciences and healthcare sectors through partnerships and tailored R&D projects. The company offers customized pricing plans based on specific project requirements, which may include subscription-based services for ongoing bioinformatics support or one-time fees for specific analyses related to NGS data. Their flagship offerings involve the development of mathematical models and bioinformatics pipelines that aid in microbial community analysis and in pharmacokinetics and pharmacodynamics modeling for drug development targeting the microbiome. Through these strategic collaborations, Biomathematica generates revenue by providing specialized services that align with the unique needs of their clients in the microbiome research field.Looking ahead, BioMathematica is focused on launching new bioinformatics products aimed at enhancing its service offerings. The company is also pursuing expansion into new markets, particularly targeting regions in Asia by the end of 2024. The recent Seed funding raised in June 2018 will be utilized to support these initiatives, further enhancing their research capabilities and product development.

## Funding rounds

- Seed, Jun 15, 2018 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed